Intellia Therapeutics Announces the Appointment of Dr. Sapna


Intellia Therapeutics Announces the Appointment of Dr. Sapna
For information contact:
Sarah Millman
(857) 285-6226
[email protected]
Intellia Therapeutics Announces the Appointment of Dr. Sapna Srivastava as Chief Finance &
Strategy Officer
CAMBRIDGE, Mass., April 22, 2015—Intellia Therapeutics, founded to develop curative medicines
utilizing CRISPR/Cas9 technology for gene editing and repair, announced today the appointment of Dr.
Sapna Srivastava as Chief Financial and Strategy Officer.
“Our management team is being further enhanced by the addition of Dr. Sapna Srivastava,” said Nessan
Bermingham, PhD, Chief Executive Officer of Intellia. “As a leading Wall Street biotechnology analyst for
over a decade, as well as a business and strategy advisor to biopharmaceutical companies, Sapna’s
extensive experience and understanding of the industry and capital markets will contribute to the
implementation and advancement of our product development, partnering and financing strategies.”
Dr. Srivastava has more than a decade of experience in the biopharmaceutical industry and Wall Street.
She was the senior analyst and team leader of the biotechnology group at Goldman Sachs. Prior to that
role, Dr. Srivastava was the senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners,
LLC, and began her career as a research associate at JP Morgan. Since 2012, Dr. Srivastava has served
as an independent strategy advisor to several high growth potential, therapeutic focused, biotechnology
companies, and co-founded a neuroscience focused biotechnology company. Dr. Srivastava received her
PhD in neuroscience from New York University.
“Intellia is a remarkable combination of world class science and people. I am delighted to join the Intellia
team, taking a direct role in helping to build this revolutionary CRISPR/Cas9 technology, which has the
potential to change the course of medicine," said Dr. Srivastava. "I’m excited to be part of the Intellia
team, which is focused on realizing the potential of this technology to develop drugs for patients with
significant unmet medical needs. I am looking forward to helping to contribute and accelerate the
company’s growth in this new position.”
About Intellia Therapeutics
Intellia Therapeutics was formed in 2014 to develop curative medicines, utilizing the promise of the
CRISPR/Cas9 technology. Intellia holds exclusive access to one of the broadest intellectual property
platforms available for the therapeutic use of CRISPR/Cas9. Intellia is backed by Atlas Venture and
Novartis Institutes for Biomedical Research. In January of this year, Intellia Therapeutics announced a
large partnering deal with Novartis for CAR-T and HSC applications of the technology. For more
information, please visit